NovoCure Limited (NVCR) Stock Analysis
Healthcare · Medical Devices
Sell if holding. Engine safety override at $17.75: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its... Read more
Sell if holding. Engine safety override at $17.75: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.4/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 68d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent Developments — NovoCure Limited
Latest news
- NVCR Director Vernon Anthony Acquires 21,500 Shares April 28 - Meyka — Meyka positive
- NovoCure Limited (NVCR) Reports Strong Q1 2026 Results and FDA A - GuruFocus — GuruFocus positive
- Novocure (NVCR) Shares Jump 22% on Strong Q1 Revenue and Raised Outlook - GuruFocus — GuruFocus positive
- NovoCure (NASDAQ:NVCR) Shares Gap Up - Should You Buy? - MarketBeat — MarketBeat positive
- NVCR Stock Update: Insights on Current Market Trends - GuruFocus — GuruFocus neutral
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -25.7%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $17.75: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $16.35. Score 5.4/10, moderate confidence.
Take-profit target: $22.87 (+30.1% upside). Prior stop was $16.35. Stop-loss: $16.35.
Quality below floor (3.9 < 4.0).
NovoCure Limited trades at a P/E of N/A (forward -15.0). TrendMatrix value score: 8.7/10. Verdict: Sell.
13 analysts cover NVCR with a consensus score of 4.1/5. Average price target: $26.
What does NovoCure Limited do?NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating...
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.